OCUL notice to sell 2,810 common shares

OCUL submitted a notice to sell 2,810 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/22/2026.

Rhea-AI Filing Summary

OCUL submitted a notice to sell 2,810 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/22/2026.

Shares outstanding were 217,691,779 as of 02/23/2026. The excerpt also shows a prior sale of 3,007 common shares on 11/24/2025 for $36,150.15.

Insights

Securities Compliance Counsel

Notice filed for resale of vested restricted shares; administrative disclosure.

The filing lists 2,810 common shares tied to restricted stock vesting under a registered plan with an action date of 02/22/2026. The filing characterizes the position as stemming from issuer‑granted restricted stock.

Shareholders and advisers should note the baseline share count of 217,691,779 as of 02/23/2026. Cash‑flow treatment for the listed shares is not specified in the excerpt; subsequent transaction details depend on holder decisions and resale mechanics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does OCUL's Form 144 disclose about the sale?

The filing discloses a proposed sale of 2,810 common shares tied to restricted stock vesting on 02/22/2026. The notice lists the instrument type and vesting origin under a registered plan; sale mechanics are not detailed in the excerpt.

How many shares of OCUL were outstanding per the filing?

The excerpt lists 217,691,779 shares outstanding as of 02/23/2026. This figure is provided in the filing and is presented here as a baseline context for the disclosed proposed sale.

Did OCUL report any recent insider sales in the past three months?

Yes; the excerpt shows a prior sale of 3,007 common shares on 11/24/2025 associated with Peter Kazuo Kaiser, with an amount shown as $36,150.15 in the table.

Is the proposed sale by OCUL subject to restrictions or approvals?

The shares are described as restricted stock vesting under a registered plan, indicating the sale arises from vesting under an existing plan. The filing text includes that characterization; no additional approvals or qualifiers are provided in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002011869
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	15 Crosby Drive Bedford MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	PETER KAZUO KAISER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2810	23267.64	217691779	02/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/22/2026	Restricted stock vesting under a registered plan	Issuer			2810	02/22/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER KAZUO KAISER 15 Crosby Drive Bedford MA 01730	Common	11/24/2025	3007	36150.15

144: Remarks and Signature

Remarks
Date of Notice	02/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Peter Kazuo Kaiser
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)